George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.82
Bid: 3.70
Ask: 3.94
Change: 0.01 (0.26%)
Spread: 0.24 (6.486%)
Open: 3.81
High: 0.00
Low: 0.00
Prev. Close: 3.81
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

22 Nov 2023 07:00

RNS Number : 2049U
Plant Health Care PLC
22 November 2023
 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

Trading update

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is announcing an update on trading and the outlook for the full year to 31 December 2023 ("FY23").

 

Highlights

 

· Market conditions in the wider agriculture market have diminished over the course of the year, particularly in the recent months;

· Due to these challenging market conditions, particularly in the key USA end market, the Company now anticipates revenue in FY2023 to be in line with or show modest growth over the year ended 31 December 2022 ("FY22"); 

· The Company continues to make significant progress in obtaining new product registrations and widening geographic distribution, positioning the Company well for growth in 2024 and beyond;

· Trading in Brazil, Mexico and Europe broadly in line with market expectations.

 

As highlighted at the time of the Company's interim results in September 2023, market conditions for traditional agriculture input businesses were extremely challenging in the first half of the year, and the environment has continued to deteriorate over recent months. This has been particularly evident in the US; however, global markets, including Brazil, Europe and some Asian markets, have also been subdued, leading a number of companies across the sector to revise guidance on current year performance.

 

Pleasingly, Plant Health Care's trading in Brazil, Mexico and Europe has been broadly in line with market expectations in the second half of the year, in spite of these challenging market conditions. However, sales orders in the US have not materialised as originally anticipated as the Company's distribution partners in the region have gone through a significant inventory correction. This has, in large part, been driven by volatility in demand and price following the global COVID-19 pandemic, as well as the effects of an increasing interest rate environment and change in growers purchasing habits. Distributors are shifting demand from Q4 FY23 into H1 FY24 and are planning to manage lower levels of inventory for FY24. While inventories of the Company's products with distributors are not high, it is not immune to this structural change. In addition, regulatory delays in India and a number of other countries have resulted in delays to some product launches; whilst this is expected to have a limited impact on the Company in FY23, this is likely to affect performance more materially in FY24.

 

Accordingly, the Board now anticipates revenue for FY23 to show flat to modest growth over FY22, with the final result dependent on the timing of expected orders. Revenue in FY24 is now anticipated to be approximately 28% lower than market expectations of $23m, due to lower levels of inventory being maintained by the Company's distributors and regulatory delays in some territories. The Board intends to review operating expenses accordingly.

 

Against this backdrop, the pace of new product registrations and the widening of distribution partnerships into new geographies continues. Sales of Harpin£ are increasing in all of the Company's core markets, excluding the US market. Critically, the first products from the new PREtec platform are being well received in the market, with successful product launches across three continents. Although there are some delays to product launches, the growth trajectory is clear for the medium term. After more than 10 years and an investment in excess of $30m, PREtec product adoption is poised for a significant step up from distributors and end customers. Accordingly, the Board is confident that order intake will increase once our customers have corrected their inventory levels.

 

Jeff Tweedy, Chief Executive Officer, commented:

 

"Sales of Plant Health Care products experienced significant growth in all regions with the exception of the US market. Deteriorating market conditions driven by distributor destocking of channel inventories impacted PHC sales in the US. Registration delays have impacted our 2024 outlook; however, we remain positive on the revenue growth opportunities for our technology. PHC now markets PREtec on three continents and we anticipate the launch of Teikko in Brazil during the 2024/2025 growing season."

 

For further information, please contact:

 

Plant Health Care plc

Tel: +1 919 926 1600

Jeff Tweedy, CEO

 

Cavendish Capital Markets Limited - Nomad & Broker

Tel: +44 (0) 131 220 9771

Neil McDonald / Peter Lynch

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes, and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUAORROSUAUUA
Date   Source Headline
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.